The aim of the study was to show a reduction in LDL cholesterol with the use of monoclonal antibody alirocumab as an adjunct therapy to statins in patients already receiving the maximum tolerated dose of statins. This study randomized 720 patients with hypercholesterolemia and high cardiovascular risk to alirocumab 75 mg subcutaneously every 2 weeks…